Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials.
<h4>Background</h4>Mesenchymal stromal cells (MSCs, "adult stem cells") have been widely used experimentally in a variety of clinical contexts. There is interest in using these cells in critical illness, however, the safety profile of these cells is not well known. We thus cond...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b8655dd2afe54445977d83005acb0f1c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:b8655dd2afe54445977d83005acb0f1c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:b8655dd2afe54445977d83005acb0f1c2021-11-18T08:11:02ZSafety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials.1932-620310.1371/journal.pone.0047559https://doaj.org/article/b8655dd2afe54445977d83005acb0f1c2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23133515/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Mesenchymal stromal cells (MSCs, "adult stem cells") have been widely used experimentally in a variety of clinical contexts. There is interest in using these cells in critical illness, however, the safety profile of these cells is not well known. We thus conducted a systematic review of clinical trials that examined the use MSCs to evaluate their safety.<h4>Methods and findings</h4>MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (to June 2011), were searched. Prospective clinical trials that used intravascular delivery of MSCs (intravenously or intra-arterially) in adult populations or mixed adult and pediatric populations were identified. Studies using differentiated MSCs or additional cell types were excluded. The primary outcome adverse events were grouped according to immediate events (acute infusional toxicity, fever), organ system complications, infection, and longer term adverse events (death, malignancy). 2347 citations were reviewed and 36 studies met inclusion criteria. A total of 1012 participants with clinical conditions of ischemic stroke, Crohn's disease, cardiomyopathy, myocardial infarction, graft versus host disease, and healthy volunteers were included. Eight studies were randomized control trials (RCTs) and enrolled 321 participants. Meta-analysis of the RCTs did not detect an association between acute infusional toxicity, organ system complications, infection, death or malignancy. There was a significant association between MSCs and transient fever.<h4>Conclusions</h4>Based on the current clinical trials, MSC therapy appears safe. However, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs.Manoj M LaluLauralyn McIntyreChristina PuglieseDean FergussonBrent W WinstonJohn C MarshallJohn GrantonDuncan J StewartCanadian Critical Care Trials GroupPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 10, p e47559 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Manoj M Lalu Lauralyn McIntyre Christina Pugliese Dean Fergusson Brent W Winston John C Marshall John Granton Duncan J Stewart Canadian Critical Care Trials Group Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. |
| description |
<h4>Background</h4>Mesenchymal stromal cells (MSCs, "adult stem cells") have been widely used experimentally in a variety of clinical contexts. There is interest in using these cells in critical illness, however, the safety profile of these cells is not well known. We thus conducted a systematic review of clinical trials that examined the use MSCs to evaluate their safety.<h4>Methods and findings</h4>MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (to June 2011), were searched. Prospective clinical trials that used intravascular delivery of MSCs (intravenously or intra-arterially) in adult populations or mixed adult and pediatric populations were identified. Studies using differentiated MSCs or additional cell types were excluded. The primary outcome adverse events were grouped according to immediate events (acute infusional toxicity, fever), organ system complications, infection, and longer term adverse events (death, malignancy). 2347 citations were reviewed and 36 studies met inclusion criteria. A total of 1012 participants with clinical conditions of ischemic stroke, Crohn's disease, cardiomyopathy, myocardial infarction, graft versus host disease, and healthy volunteers were included. Eight studies were randomized control trials (RCTs) and enrolled 321 participants. Meta-analysis of the RCTs did not detect an association between acute infusional toxicity, organ system complications, infection, death or malignancy. There was a significant association between MSCs and transient fever.<h4>Conclusions</h4>Based on the current clinical trials, MSC therapy appears safe. However, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs. |
| format |
article |
| author |
Manoj M Lalu Lauralyn McIntyre Christina Pugliese Dean Fergusson Brent W Winston John C Marshall John Granton Duncan J Stewart Canadian Critical Care Trials Group |
| author_facet |
Manoj M Lalu Lauralyn McIntyre Christina Pugliese Dean Fergusson Brent W Winston John C Marshall John Granton Duncan J Stewart Canadian Critical Care Trials Group |
| author_sort |
Manoj M Lalu |
| title |
Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. |
| title_short |
Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. |
| title_full |
Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. |
| title_fullStr |
Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. |
| title_full_unstemmed |
Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. |
| title_sort |
safety of cell therapy with mesenchymal stromal cells (safecell): a systematic review and meta-analysis of clinical trials. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/b8655dd2afe54445977d83005acb0f1c |
| work_keys_str_mv |
AT manojmlalu safetyofcelltherapywithmesenchymalstromalcellssafecellasystematicreviewandmetaanalysisofclinicaltrials AT lauralynmcintyre safetyofcelltherapywithmesenchymalstromalcellssafecellasystematicreviewandmetaanalysisofclinicaltrials AT christinapugliese safetyofcelltherapywithmesenchymalstromalcellssafecellasystematicreviewandmetaanalysisofclinicaltrials AT deanfergusson safetyofcelltherapywithmesenchymalstromalcellssafecellasystematicreviewandmetaanalysisofclinicaltrials AT brentwwinston safetyofcelltherapywithmesenchymalstromalcellssafecellasystematicreviewandmetaanalysisofclinicaltrials AT johncmarshall safetyofcelltherapywithmesenchymalstromalcellssafecellasystematicreviewandmetaanalysisofclinicaltrials AT johngranton safetyofcelltherapywithmesenchymalstromalcellssafecellasystematicreviewandmetaanalysisofclinicaltrials AT duncanjstewart safetyofcelltherapywithmesenchymalstromalcellssafecellasystematicreviewandmetaanalysisofclinicaltrials AT canadiancriticalcaretrialsgroup safetyofcelltherapywithmesenchymalstromalcellssafecellasystematicreviewandmetaanalysisofclinicaltrials |
| _version_ |
1718422130750652416 |